Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam vs Propofol for Procedural Sedation in TEE
NCT07829458Phase 4Not yet recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Sep 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 4, randomised trial of remimazolam (2 arms), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: Incidence of intra-procedural hypotension. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
remimazolam
Beyond the preview
Go deeper on NCT07829458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07829458.